Intelligent robotics dramatically improves pathology workflow and uses proprietary inputs for next-generation precision medicine and care paradigms.
FREMONT, CA: Smart robots automate regular operations, alleviate physical demands on human workers, and assure process consistency. These robots can keep track of inventory and arrange timely orders, assisting in distributing supplies, equipment, and medication. One of the leading robotics companies in pathology processing, Clarapath, has secured an additional investment of $16 million to the company's Series B round after securing $16 million in Series B funding round. East Post Road Ventures (White Plainsl HospitaInvstmeent Arm), Epiphron Capital, Northwell Ventures, P5 Health Ventures, and other strategic organizations participated in the investment. Since its inception, Clarapath has raised over $39 million. Clarapath is automating sections or cutting a cross-section of the tissue specimen into glass slides.
“Long overdue for a change, the current process is entirely manual, non-scalable, and is dependent on a shrinking workforce. The COVID-19 pandemic has exacerbated labor shortages, creating unacceptable delays in the delivery of timely biopsy results and driving up healthcare costs. Being a manual process, AI-driven algorithms for interpretation of human tissues - particularly cancer - when examined on a cellular level are vulnerable to the variability in the quality of those tissue cross sections. Clarapath’sSectionStar consolidates many manual cutting, quality control, and decision making steps into one piece of equipment, resulting in better quality tissue sections, faster processing efficiencies, and lower overall costs, all while providing richer data sets on those tissue specimens,” states Eric Feinstein, CEO of Clarapath, who was recently named one of the 40 under 40 Rising Stars by The Business Council of Westchester.
A fully automated technology dubbed SectionStar revolutionizes the pathology laboratory's dependability and efficiency. It is essential to discover new therapeutic pathways and the molecular mapping of human disease to have the same quality tissue sections.
“This funding will help further develop SectionStar with the goal of launching in the non-clinical market in the very near future, and targeting the large clinical market as our ultimate goal. The current funding will help us continue building our team, as well as supporting a robust sales and service effort for our customers,” adds Feinstein.
The Ellison Institute and Northwell Health are two of Clarapath's current clinical and research customers. SectionStar will assist in pharmaceutical R&D conducted outside of a clinical setting. "Conventional tissue processing based on 2D sections lacks 3D context. The undistorted, consecutive section cut by the robotic device allows overlaying molecular and genomic markers. These data sets combined with advanced computational analyses can transform non-clinical research in diagnosing and developing therapies for cancer and other challenging diseases," says ParthaMitra, PhD, Founder of Clarapath.